Trial · NCT01379898
Phenoxybenzamine Versus Doxazosin in PCC Patients
NCT01379898, Phase 4, Completed, University Medical Center Groningen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phenoxybenzamine Versus Doxazosin in PCC Patients. Trials, record NCT01379898. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01379898
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phenoxybenzamine Versus Doxazosin in PCC Patients
- NCT number
- NCT01379898
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 134 participants, actual
- Lead sponsor
- University Medical Center Groningen
- Conditions
- Pheochromocytoma
- Interventions
- Phenoxybenzamine, Doxazosin
- First posted
- 2011-06-23
- Last updated
- 2024-09-19
- Other registries' IDs
- eudract:2010-022417-25
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The main study parameter is defined as the percentage of intraoperative time that blood pressure is outside the predefined target range after pretreatment with either phenoxybenzamine or doxazosin. | Duration of surgery, i.e. on average 3 hours | Blood pressure and heart rate will be monitored continuesly during surgery. |
| Secondary | To attain preoperative blood pressure target values without co-medication | an expected average of 2 to 6 weeks before surgery | success rate of doxazosin and phenoxybenzamine to attain preoperative blood pressure target values without co-medication |
| Secondary | Resolution of (paroxysmal) symptoms and signs of pheochromocytoma. | an expected average of 2-6 weeks before surgery | Resulution of headache, palpitations, sweeting, paleness, nausea, flushes, fatigue and anxiety. |
| Secondary | Need for additional antihypertensive agents | an expected average of 2-6 weeks before surgery | Assessment of the number of patients who need additional antihypertensive drugs on top of the study drugs |
| Secondary | Adverse effects of study medication | an expected average of 2-6 weeks before surgery | Adverse effects of doxazosin or phenoxybenzamine |
| Secondary | Length of preoperative treatment in either outpatient or inpatient clinic. | an expected average of 2-6 weeks before surgery | Comparing duration of preoperative treatment in either outpatient or inpatient clinic |
| Secondary | Control of blood pressure and heart rate. | Duration of surgery, i.e. on average 3 hours | * number of episodes with systolic blood pressure (SBP) \> 160 mmHg * number of episodes with mean arterial blood pressure (MAP) \< 60 mmHg * duration (in minutes) of SBP \> 160 mmHg * duration (in minutes) of MAP \< 60 mmHg * number of episodes with heart rate \> 100/min * duration (in minutes) of heart rate \> 100/min * amount and type of vasoactive agents needed during surgery for adequate blood pressure control. * cumulative amount and type of intravenous fluids administered |
| Secondary | Length of hospital stay. | Participants will be followed for the duration of hospital stay an expected average of 2-5 weeks. | Number of days the patient is staying in the hospital before and after surgery |
| Secondary | Composite semi-quantitative score of intra- and postoperative hemodynamic control. | During surgery and the first 24 hours after surgery at the intensive/ medium care unit | Composite semi-quantitative score of intra- and postoperative hemodynamic control based on the following parameters: * blood pressure and heart rate outside target range * need for administration of vasoactive agents * need for administration of intravenous fluids |
| Secondary | Postoperative hypoglycaemia | First 24 hours postoperative | Frequency and severity (in mmol/L)of hypoglycaemia during first 24 hours after surgery. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01379898
GET https://conductscience.org/api/trials/v1/NCT01379898/papers?page=2